期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
安罗替尼三线以上治疗非小细胞肺癌疗效观察 被引量:7
1
作者 卢美君 康马飞 +3 位作者 李碧慧 徐胜源 石洁琼 赵燕仪 《现代肿瘤医学》 CAS 北大核心 2021年第8期1332-1335,共4页
目的:观察安罗替尼在晚期非小细胞肺癌三线以上治疗中的疗效和不良反应。方法:二线或多线治疗后进展的晚期非小细胞肺癌患者75例(其中55例为二线治疗后,15例为三线治疗后,5例为4线治疗后)。所有患者均给予安罗替尼12 mg,每天1次口服,连... 目的:观察安罗替尼在晚期非小细胞肺癌三线以上治疗中的疗效和不良反应。方法:二线或多线治疗后进展的晚期非小细胞肺癌患者75例(其中55例为二线治疗后,15例为三线治疗后,5例为4线治疗后)。所有患者均给予安罗替尼12 mg,每天1次口服,连续服用14天,停用1周,每21天重复,直到疾病进展或不能耐受不良反应为止。不能耐受不良反应的患者,根据情况将剂量降至每天10 mg或每天8 mg。每6周复查CT评价疗效。结果:75例患者中,PR 6例,SD 45例,PD 24例,ORR 8.0%,DCR 60.0%,PD 32.0%,PFS和OS分别为5.2个月(95%CI:4.4~6.0)和8.0个月(95%CI:6.1~9.9)。分层结果,45例腺癌中,PR 4例,SD 27例,PD 14例,ORR 8.9%,DCR 68.9%,PD 31.1%。30例鳞状细胞癌中,PR 2例,SD 18例,PD 10例,ORR 6.7%,DCR 66.7%,PD 33.3%。腺癌组与鳞状细胞癌组的DCR比较,P=0.840,无统计学差异,腺癌组与鳞状细胞癌组的PFS分别为4.5个月(95%CI:3.9~5.1)和5.2个月(95%CI:4.2~6.2),Log-Rank P=0.033,有统计学差异,OS分别为6.7个月(95%CI:3.2~10.2)和8.0个月(95%CI:5.9~10.1),Log-Rank P=0.057,无统计学差异。不良反应主要是疲劳、食欲减退、手足综合征、头痛和高血压。结论:安罗替尼三线以上治疗非小细胞肺癌有效,鳞状细胞癌患者的PFS显著高于腺癌患者,不良反应可以耐受。 展开更多
关键词 肺肿瘤/肺癌 非小细胞肺癌 分子靶向治疗 安罗替尼
下载PDF
HRCT Scans of Peripheral Non-Small Cell Lung Cancers and their Relationship with Cyclin D1 Expression:a Longitudinal Study
2
作者 Shuhua Ma Linfa Wu +9 位作者 Xiaomao Xu Hongbo Le Xiaoling Cheng Huihong Zhang Zhengyu Sun Zhaoxin Wang Min Wu Wei Mei Zhiguo Hu Yuguang Li 《Chinese Journal of Clinical Oncology》 CSCD 2008年第3期172-178,共7页
OBJECTIVE To investigate cyclin D1 expression in peripheral lung cancers and its relationship with CT signs and prognosis. METHODS Cyclin D1 expression in peripheral lung cancers and its relationship with the CT imagi... OBJECTIVE To investigate cyclin D1 expression in peripheral lung cancers and its relationship with CT signs and prognosis. METHODS Cyclin D1 expression in peripheral lung cancers and its relationship with the CT imaging and prognosis were analyzed retrospectively by means of SP immunohistochemistry and spiral CT scanning in 92 patients with peripheral lung cancer verified by pathology. RESULTS Cyclin D1 expression was related to deep lobulation,spiculate protuberance,short thin spinules sign and mediastina lymph node metastasis.Cyclin D1 expression was not related to tumor size,cavity,pleural indentation,histological type,differentiation,tumor TNM stage,age or sex.Cyclin D1 was a negative prognostic factor whose over-expression indicated a poor prognosis. CONCLUSION Cyclin D1 expression may play an important role in the occurrence,progress and CT scan results of lung cancers.Cyclin D1 was a negative factor whose over-expression implied a poor prognosis.Detection of the cyclin D1 and observation of the CT scan can be considered as indexes of clinical diagnosis and prognostic evaluation. 展开更多
关键词 lung neoplasms cyclin D1 computed tomography.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部